SCHEMBL28022074

SCHEMBL28022074

c1c[nH]nn1.c1cnc2cccnc2c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.43
MAPT P10636 3/20 0.39
KDM4E B2RXH2 2/20 0.39
NR4A2 P43354 2/20 0.35
ATAD2 Q6PL18 1/20 0.34
POLB P06746 2/20 0.33
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
AXL P30530 1/20 0.33
NUDT1 P36639 1/20 0.33
PDGFRB P09619 1/20 0.33
PDGFRA P16234 1/20 0.33
CYP3A4 P08684 1/20 0.32
HTT P42858 3/20 0.31
MEN1 O00255 2/20 0.31
CASP1 P29466 2/20 0.31
KMT2A Q03164 2/20 0.31
LMNA P02545 2/20 0.31
HSP90AA1 P07900 2/20 0.31
HSP90AB1 P08238 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Quinoxaline SCHEMBL3988599 0.91 ALDH1A1 (0.38) ALDH1A1MAPTKDM4EPOLBMEN1
Quinoxaline SCHEMBL28050792 0.89 ALDH1A1 (0.37) ALDH1A1MAPTKDM4EPOLBMEN1
Quinoline SCHEMBL14977039 0.88 ALDH1A1 (0.63) ALDH1A1MAPTKDM4ENR4A2POLB
Quinoline SCHEMBL27314055 0.87 ALDH1A1 (0.61) ALDH1A1MAPTKDM4ENR4A2POLB
SCHEMBL28055407 0.86 EGFR (0.38) ALDH1A1MAPTKDM4E
SCHEMBL28663518 0.81 PSMD14 (0.42) ALDH1A1MAPTKDM4ENR4A2ATAD2
Phenazine SCHEMBL28755011 0.80 MAPT (0.50) ALDH1A1MAPTKDM4EPOLBNPC1
Phenazine SCHEMBL28755089 0.80 MAPT (0.50) ALDH1A1MAPTKDM4EPOLBNPC1
SCHEMBL28021437 0.79 GRM5 (0.42) KDM4EPOLBNPC1RAB9AMEN1
Dipyridyl SCHEMBL15401742 0.77 KDM4E (0.58) ALDH1A1MAPTKDM4EPOLBNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105492011-A Therapeutic synergy of undesirable chemical compounds BROWN DENNIS M 2016-04-13 CN disclosed
CN-104797267-A Method of treating tyrosine kinase inhibitor-resistant malignancies in patients with genetic polymorphism or AHI1 dysregulation or mutation using dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof DEL MAR PHARMACEUTICALS 2015-07-22 CN disclosed